Timeline
AstraZeneca's Truqap approved in US as targeted treatment for prostate cancer
Health & Bio Today: BSF Enterprise shares halve after T-Rex handbag fails at auction, Cizzle Biotechnology, GSK
Tech Today: Pennant wins C$35m Canadian Navy contract, Pri0r1ty Intelligence, MedPal AI
UK approval for first oral GLP-1 weight-loss pill will open private market opportunity, MedPal tells investors
GSK wins orphan drug status in US and Europe for momelotinib in rare inflammatory blood disorder with no approved treatments
Poolbeg activates first site for POLB 001 TOPICAL trial
Safestore forecasts return to earnings growth but warns higher rates will cap EPS
Vivoryon says cash will fund operations into Q4 2026 as it pushes varoglutamstat toward Phase 2b in DKD
Poolbeg presents POLB 001 preclinical data showing CRS reduction and potential AML benefit
Health & Bio Today: GSK acquires Nuvalent for $10.6bn, Imaging Biometrics, Seaport Therapeutics, Smith+Nephew
Oil & Gas Today: Zephyr Energy clears Paradox pipeline for gas export push, Vaalco Energy, Afentra, Wildcat Petroleum
PureTech's Seaport advances GlyphAgo into Phase 2 after positive Phase 1 multiple‑dose data
Imaging Biometrics publishes Phase 1 gallium trial and reopens access programme
Zephyr Energy clears pipeline inspection and starts regulatory push to export Paradox gas
GSK to buy Nuvalent for $10.6bn to add late‑stage lung‑cancer drugs
Aptamer Group launches Gates Foundation‑backed programme to build rapid folate test
Health & Bio Today: Incanthera acquires Énielle skincare brand, Crism Therapeutics, Eco Animal Health
ECO Animal Health renews £10m rolling credit and £5m overdraft
Pennant launches major Auxilium update for "future‑ready foundation"
Novo Nordisk launches Wegovypill in the UAE
Health & Bio Today: ValiRx walks away from Stingray licence, Verici Dx, Inspiration Healthcare, Hammerson
ValiRx shares tumbled after Stingray evaluation ends
Oxford Biomedica's investor day can kick of a rerating and reignite sentiments
Elementis shares up on sale of pharmaceutical manufacturing business
Hammerson prices EUR350m five-year bond and extends credit facilities
Health & Bio Today: Avacta reports positive salivary gland cancer data, hVIVO, ValiRx, CRISM Therapeutics, ProBiotix Health
hVIVO signs consultancy deal with Decoy Therapeutics to advance multi‑virus antivirals
Applied Nutrition shares bulk up on acquisition and Mondelēz collab
CRISM Therapeutics lands Northern Ireland grant for ChemoSeed prostate programme
ValiRx exercises RNA option after evaluation finishes four months early
Health & Bio Today: CelLBxHealth wins AstraZeneca services deal, Avacta Group, AstraZeneca
CelLBxHealth shares rocket on AstraZeneca master services agreement
AstraZeneca wins US approval for Imfinzi in early high‑risk bladder cancer
Health & Bio Today: GSK, BSF Enterprise, Nuformix, Physiomics, SkinBioTherapeutics, Property Franchise Group
GSK posts positive Phase 3 results for Hepatitis B treatment
Physiomics builds hantavirus translational modelling framework
Nuformix results highlight progress as it advances 'viable and attractive' candidates
Health & Bio Today: ImmuPharma narrows loss with P140 partnership push, Physiomics, ValiRx, AstraZeneca
ImmuPharma narrows loss, highlights post-period fundraise
Physiomics secures more modelling and data-science contracts
ValiRx's Cytolytix secures European patent for nanoparticle delivery
AstraZeneca says FDA extends decision date for camizestrant, allowing extra data review
Health & Bio Today: Genedrive chairman exits as Nugent joins board, Novo Nordisk, Crism, Diaceutics, CVS Group, AstraZeneca,
Novo Nordisk study finds two in five high‑risk cardiovascular patients have persistent inflammation
The Premarket Brief: Sound Energy sells Tendrara stake for $57m, CVS Group, Arrow Exploration, AstraZeneca, Atalaya Mining
AstraZeneca wins CHMP backing for Enhertu tumour‑agnostic approval
Health & Bio Today: EMV Capital spotlights XF-73 ahead of Phase 3, IXICO, Oxford Nanopore, AstraZeneca
Broker calls AstraZeneca pipeline news “frenetic”, repeats Sell rating
EMV Capital commercial update spotlights XF-73 as it moves toward Phase 3
More in Healthcare
Genedrive's personalised medicine receives Parliament boost
A government minister named Genedrive's newborn hearing-loss test as a live example of personalised medicine during a House of Commons committee session.